Perceived walking difficulties in Parkinson's disease – predictors and changes over time

Magnus Lindh-Rengifo (✉ magnus.lindh-rengifo@med.lu.se)

Lunds universitet Medicinska fakulteten <https://orcid.org/0000-0002-2336-4881>

Stina B. Jonasson

Memory Clinic, Skåne University Hospital

Susann Ullén

Clinical Studies Sweden - Forum South, Skåne University Hospital, Lund

Niklas Mattsson-Carlsson

Department of Neurology, Skåne University Hospital, Lund

Maria H. Nilsson

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University

Research article

Keywords: Perceived walking difficulties, Parkinson Disease, Mobility limitation, Prediction, Multivariable regression

Posted Date: September 9th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-60246/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Geriatrics on April 1st, 2021. See the published version at <https://doi.org/10.1186/s12877-021-02113-0>.

Abstract

Background

People with Parkinson's disease (PD) have described their walking difficulties as linked to activity avoidance, social isolation, reduced independence and quality of life. There is a knowledge gap regarding predictive factors of perceived walking difficulties in people with PD. Such knowledge could be useful when designing intervention studies. This study aimed to investigate how perceived walking difficulties evolve over a 3-year period in people with PD. A specific aim was to identify predictive factors of perceived walking difficulties.

Methods

149 people with PD (mean age 67.9 years) completed the Walk-12G questionnaire (which assesses perceived walking difficulties) at both baseline and the 3-year follow-up. Paired samples t-test was used for comparing baseline and follow-up mean scores. Multivariable linear regression analyses were used to identify predictive factors of perceived walking difficulties.

Results

Perceived walking difficulties increased after 3 years: mean Walk-12G score 14.7 versus 18.6, $p < 0.001$. Concerns about falling was the strongest predictor ($\beta = 0.467$) of perceived walking difficulties, followed by problems maintaining balance while dual tasking ($\beta = 0.265$), pain ($\beta = 0.137$) and postural instability ($\beta = 0.116$). Problems maintaining balance while dual tasking was the strongest predictor ($\beta = 0.180$) of a change in perceived walking difficulties, followed postural instability ($\beta = 0.098$).

Conclusions

Perceived walking difficulties increase over time in people with PD. The predictive factors identified in this study (concerns about falling, problems maintaining balance while dual tasking, pain, postural instability) are modifiable. Future intervention studies that address these factors need to confirm their preventative effect on perceived walking difficulties.

Background

Walking difficulties are common in people with Parkinson's disease (PD) ¹ and are associated with a loss of independence ², activity limitations ^{3,4}, falls ⁵ as well as decreased social participation ⁶ and quality of life ⁷. Gait patterns change at an early stage of PD ⁸, and increases further if combined with dual tasking ⁹, i.e. simultaneous performance of a cognitive or motor task while walking. All considered, this makes it

important to assess and address walking difficulties in PD. An increased knowledge of factors that predict walking difficulties could nurture the development of future preventative and rehabilitative approaches. Several studies have identified factors that predict objective gait difficulties in people with PD ^{10–12}, e.g. older age, longer disease duration, worse disease severity, and lower balance confidence ^{10,11}. Less is known about predictive factors of perceived walking difficulties.

Qualitative studies that involved people with PD have described that walking difficulties relate to both motor and non-motor factors, such as freezing of gait (i.e. FOG), fear of falling, pain and fatigue ^{13,14}. Sudden changes in their walking ability induce an uncertainty whether they will manage activities or not ^{6,15}. On the other hand, belief in their walking ability can serve as an enabler of physical activity and participation in socially meaningful activities ⁶.

Cross-sectional quantitative studies that addressed perceived walking difficulties in people with PD have identified several associated factors. One study found that two objective gait domains (i.e. pace and variability) were moderately associated with perceived walking difficulties ¹⁶. Another cross-sectional study, based on the same sample as the present study, identified FOG as the strongest contributing factor, followed by general self-efficacy, fatigue, PD duration, lower extremity function, orthostatic hypotension, bradykinesia and postural instability ¹⁷. However, a longitudinal study design is a prerequisite for identifying predictive factors; this is lacking in relation to perceived walking difficulties in people with PD.

This study aimed to investigate how perceived walking difficulties evolve over a 3-year period in people with PD. A specific aim was to identify predictive factors of perceived walking difficulties.

Methods

This study used longitudinal data, collected in a larger project: “Home and Health in People Ageing with Parkinson’s disease” (PI: Nilsson, MH). Baseline data collection took place in 2013 with a 3-year follow-up in 2016. A more exhaustive description of the design and methods of the project can be found in the study protocol ¹⁸.

Participants and recruitment

In the larger project, participants were recruited (outpatient context) from three hospitals in southern Sweden. PD diagnosis (ICD10-code G20.9) since at least one year constituted inclusion criterion. Exclusion criteria were as follows: difficulties understanding or speaking Swedish, living outside Skåne County, severe cognitive difficulties and/or other reasons that hindered them from giving informed consent or taking part in the majority of the data collection (e.g. hallucinations or a recent stroke).

The selection process was performed by the specialist PD nurse responsible for the patients at the outpatient clinic, i.e. at the respective hospital. In some instances, the PD nurse checked medical records

and contacted the responsible movement disorder neurologist. Flowcharts and detailed descriptions of the recruitment procedures have been previously published for the baseline ¹⁷ and the 3-year follow-up ¹⁹.

At baseline, the final sample size was 255 participants. To be considered eligible for participation at the 3-year follow-up (± 3 months), the participants should have completed the baseline assessments and then agreed to be contacted again ($n = 255$). At the 3-year follow-up, eight were unreachable and 22 persons were deceased. One person was excluded since they responded outside the follow-up window. Out of those contacted, seven additional participants were excluded, i.e. had moved outside Skåne county or had no longer the diagnosis PD. This resulted in 217 potential participants. Out of these, 51 (23.5%) declined further participation. Extensive missing data and low data quality led to that an additional person was excluded. In total, 165 participants took part in the 3-year follow-up.

An additional inclusion criterion applied for the current study; only participants with a total score on the Generic Walk-12 (Walk-12G; assesses perceived walking difficulties) questionnaire at both baseline and the 3-year follow-up were included. This rendered a final study sample of 149 participants. At baseline, their mean (SD) age was 67.9 (± 8.94) years, and 32.9% were female. Their median (q1-q3) PD duration was 8 (5-11.5) years. Median (q1-q3) PD severity during “on-state” according to the Hoehn & Yahr staging was 2 (2–3); possible scoring range 1–5 (higher = worse) ²⁰. Additional descriptive information is presented in Table 1.

Table 1

Participants' characteristics at baseline and univariable linear regression analyses with Walk-12G scores at the 3-year follow-up as the dependent variable, N = 149

Independent variables	Descriptives	Missing	Univariable regression analyses	
			B (95% CI); β	p-value
Age (years), mean (SD)	67.9 (8.94)	-	0.542 (0.338, 0.745); 0.398	< 0.001
Sex (women = 1), n (%)	49 (32.9)	-	3.53 (-0.638, 7.70); 0.137	0.096
PD duration, median (q1-q3)	8 (5-11.5)	-	0.501 (0.192, 0.811); 0.255	0.002
Concerns about falling (FES-I), median (q1-q3)	23 (18–36)	2	0.739 (0.622, 0.855); 0.721	< 0.001
Dual task: perceived balance problems (yes = 1), n (%)	89 (59.7)	-	14.4 (11.0, 17.7); 0.582	< 0.001
Postural instability (UPDRS III, item 30, scores ≥ 1 , yes = 1), n (%)	112 (75.2)	-	8.67 (4.31, 13.1); 0.309	< 0.001
Bradykinesia (UPDRS III, item 31, scores ≥ 1 , yes = 1), n (%)	88 (59.1)	-	6.13 (2.23, 10.1); 0.249	0.002
Freezing of gait (FOGQsa, item 3, scores ≥ 1 , yes = 1), n (%)	81 (54.4)	-	11.8 (8.34, 15.3); 0.485	< 0.001
Worse lower extremity function (Five chair stands test ≥ 16.0 sec, yes = 1), n (%) [†]	77 (51.7)	-	6.26 (2.44, 10.1); 0.258	0.001

Walk-12G = Generic Walk-12 (0–42, higher = worse); B = unstandardized regression coefficient; β = standardized regression coefficient; FES-I = Falls Efficacy Scale-International (16–64, higher = worse); UPDRS III = Unified Parkinson's Disease Rating Scale, motor examination (item scores 0–4, higher = worse); FOGQsa = self-administered version of the Freezing of Gait Questionnaire (item 3 scores 0–4, higher = worse); NMSQuest = Non-motor Symptoms Questionnaire; MoCA = Montreal Cognitive Assessment (0–30, higher = better); NHP-EN = Energy subscale of the Nottingham Health Profile (those who affirmed at least one out of three dichotomous questions were classified as having fatigue); GSE = General Self-Efficacy Scale (10–40, higher = better); GDS-15 = Geriatric Depression Scale (0–15, higher = worse).

[†]12 participants did not manage the test. These were categorized as having worse lower extremity function (i.e. ≥ 16 seconds).

Independent variables	Descriptives	Missing	Univariable regression analyses	
Orthostatism (NMSQuest, item 20, yes = 1), n (%)	73 (49)	-	8.31 (4.59, 12.1); 0.343	0.001
Bothered by pain (yes = 1), n (%)	94 (63.1)	-	7.39 (3.47, 11.4); 0.294	< 0.001
Cognitive functioning (MoCA), mean (SD)	25.7 (3.13)	2	-1.06 (-1.67, -0.451); -0.274	0.001
Fatigue (NHP-EN, yes = 1), n (%)	76 (51.0)	-	11.4 (7.91, 14.9); 0.470	< 0.001
General Self-Efficacy (GSE), mean (SD)	29.8 (6.38)	1	-0.624 (-0.920, -0.329); -0.327	< 0.001
Depressive symptoms (GDS-15), median (q1-q3)	2 (1-3.75)	5	1.55 (0.872, 2.23); 0.354	< 0.001
Walk-12G = Generic Walk-12 (0–42, higher = worse); B = unstandardized regression coefficient; β = standardized regression coefficient; FES-I = Falls Efficacy Scale-International (16–64, higher = worse); UPDRS III = Unified Parkinson's Disease Rating Scale, motor examination (item scores 0–4, higher = worse); FOGQsa = self-administered version of the Freezing of Gait Questionnaire (item 3 scores 0–4, higher = worse); NMSQuest = Non-motor Symptoms Questionnaire; MoCA = Montreal Cognitive Assessment (0–30, higher = better); NHP-EN = Energy subscale of the Nottingham Health Profile (those who affirmed at least one out of three dichotomous questions were classified as having fatigue); GSE = General Self-Efficacy Scale (10–40, higher = better); GDS-15 = Geriatric Depression Scale (0–15, higher = worse).				
[†] 12 participants did not manage the test. These were categorized as having worse lower extremity function (i.e. ≥ 16 seconds).				

General procedure

A self-administered postal survey preceded the home visit by about ten days. The home visit included a structured interview and clinical assessments. Baseline and the 3-year follow-up were similar in terms of general procedure and data collection. We used Walk-12G data from both baseline and the 3-year follow-up. All other data in the present study were collected at baseline.

Data collections

Perceived walking difficulties

Perceived walking difficulties was assessed by using the Walk-12G²¹, which constituted the dependent variable in this study. Walk-12G is a self-administered questionnaire, which assesses perceived walking difficulties during the past two weeks. The 12 items address various aspects of perceived walking difficulties, such as perceived limitations in the ability to climb stairs, balance problems and effort level

while walking. The summed total score ranges between 0 and 42 (higher = worse). The Walk-12G has been psychometrical evaluated and has shown to be both reliable and valid in people with PD ²¹.

Independent variables

Independent variables were selected based on results from prior cross-sectional PD studies, as well as theoretical and clinical reasoning regarding their relationship with perceived walking difficulties.

At the home visits, clinical assessments addressed different types of functioning, such as lower extremity function, bradykinesia, postural instability and global cognitive functioning. Lower extremity function was assessed by using the Five chair stands test (1 trial), which was performed “as fast as possible” ²².

Participants were categorized into two groups based on their median result: those who completed the Five chair stands test in 16.0 seconds or more were categorized as having worse lower extremity function (coded 1); this time limit is identical to the cut-off value for an increased fall-risk in people with PD ²³.

Participants that did not manage the test (n = 12) were categorized as having worse lower extremity function (i.e. coded 1). Two items of the motor part of the Unified Parkinson’s Disease Rating Scale (UPDRS III) were used: postural stability (item 30) and bradykinesia (item 31) ²⁴. The items (originally rated 0 to 4, higher = worse) were dichotomised. A score of 0 was considered as having no problem (coded 0), whereas a score of one to four was categorized as having postural instability or bradykinesia, respectively (coded 1). Global cognitive functioning was assessed by using the Montreal Cognitive Assessment (MoCA), scored 0–30 (higher = better) ²⁵.

The postal survey included several self-administered questions and questionnaires that addressed personal factors, different motor aspects and non-motor symptoms related to PD, such as general self-efficacy, concerns about falling, FOG and fatigue. General self-efficacy was assessed by using the General Self-Efficacy scale, scored 10–40 points (higher = better) ²⁶. Concerns about falling was assessed using the Falls Efficacy Scale-International (FES-I), scored 16–64 (higher = worse) ²⁷. FOG was assessed by using item 3 of the self-administered version of the Freezing of Gait Questionnaire (FOGQsa) ²⁸; item 3 is scored 0–4 (higher = worse). Those who scored > 0 were categorized as freezers ²⁹. Fatigue was evaluated using the Nottingham Health Profile, energy subscale (NHP-EN) ³⁰. Those who affirmed at least one out of three dichotomous questions were classified as having fatigue ³¹. A dichotomous (Yes/No) question addressed perceived balance problems while dual tasking: “Do you experience balance problems while standing or walking when doing more than one thing at a time, e.g. carrying a tray while walking?”¹⁸ Item 20 of the Non-Motor Symptoms Questionnaire (NMSQuest) was used for addressing orthostatism (Yes/No) ³².

Additional data collection included pain (“Are you bothered by pain?” Yes/No) and depressive symptoms, which were assessed by using the Geriatric Depression Scale (GDS-15), scored 0–15 (higher = worse) ³³. The two latter were interview-administered at the home visit. For descriptive purposes, we also reported PD duration.

Statistical analysis

The paired samples t-test was used to compare mean total scores of the Walk-12G, i.e. from baseline and the 3-year follow-up. For Walk-12 G scores, standard error of measurement (SEM) was calculated using the formula $SEM = SD_{\text{pooled}} \times \sqrt{1 - Cronbach\alpha}$. SEM was calculated for baseline and follow-up scores, respectively.

Pearson's correlation coefficients (r) were used for studying the relationship between potential independent variables in the upcoming multivariable regression analysis. There were no signs of multicollinearity between the independent variables. That is, no correlation exceeded 0.7. However, FES-I scores at baseline were strongly correlated ($r = 0.870$) with baseline Walk-12G scores, which were included as a controlling factor in one of the regression models.

Univariable linear regression analyses were used for studying the associations between the dependent variable (Walk-12G at the 3-year follow-up) and independent variables (Table 1). All associations fulfilled the criterion $p < 0.3$. Consequently, all independent variables were simultaneously included in the following multivariable linear regression analyses (method: enter) to avoid leaving out a confounding variable. As older age is strongly associated with walking difficulties in people with PD ³⁴, age was included as a controlling factor.

Model 1 identifies factors that can predict perceived walking difficulties at the 3-year follow up. A second multivariable model (i.e. Model 2) was created, controlling for baseline Walk-12G scores in order to identify predictive factors of a change in Walk-12G over a 3-year period, i.e. given the Walk-12G score at baseline. In both multivariable analyses, the estimate and p-value for each independent variable were examined; the variable with the highest p-value was manually removed from the model. This procedure continued until the p-value was < 0.1 for all remaining independent variables.

Residuals of all final multivariable models were visually inspected for normality, linearity and constant variance. Unadjusted and adjusted R^2 indicate the predictive capacity of the models. Statistical significance was set to a 0.05 level. All statistical analyses were performed using SPSS statistics, version 25 (IBM Corporation, Armonk, NY, United States).

Results

The mean (SD) Walk-12G score increased (i.e. worsened) from 14.7 (± 10.8) at baseline to 18.6 (± 12.2) three years later: mean difference 3.9, 95% confidence interval 2.6–5.2, $p < 0.001$. The SEM for Walk-12G was 2.6 at baseline, whereas it was 2.3 at the 3-year follow-up. Detailed data is presented in Table 2.

Table 2
Item and total scores of the Walk-12G (including Cronbach α and SEM), N = 149

Walk-12G items (abbreviated)	Baseline Mean (SD)	3-year follow-up Mean (SD)
1. Need to use support when walking indoors	0.62 (0.722)	0.83 (0.809)
2. Need to use support when walking outdoors	0.64 (0.848)	0.93 (0.901)
3. Limited ability to run	1.23 (0.863)	1.43 (0.832)
4. Difficult to stand when doing things	1.11 (1.15)	1.48 (1.31)
5. Limited ability to climb up and down stairs	0.97 (1.17)	1.56 (1.40)
6. Problems balancing when standing or walking	1.33 (1.15)	1.72 (1.34)
7. Limited ability to walk	1.31 (1.24)	1.68 (1.30)
8. Effortful walking	1.46 (1.20)	1.74 (1.29)
9. Smoothness of walking affected	1.48 (1.13)	1.75 (1.22)
10. Need to concentrate on walking	1.32 (1.24)	1.53 (1.30)
11. Limited walking distance	1.61 (1.40)	2.00 (1.46)
12. Slow walking	1.61 (1.15)	1.91 (1.27)
Walk-12G total score	14.7 (10.8)	18.6 (12.2) [†]
Internal consistency (Cronbach α)	0.949	0.959
Standard error of measurement, SEM	2.59	2.33
Walk-12G = Generic Walk-12. Possible scoring range for items 1–3: 0–2; items 4–12: 0–4, possible total scoring range 0–42, higher = worse. $SEM = SD_{pooled} \times \sqrt{1 - Cronbach\ \alpha}$ $SD_{pooled} = \sqrt{((SD_{baseline}^2 + SD_{3-year}^2)/2)}$ [†] $p < 0.001$, Paired Samples t Test		

<PLEASE INSERT Table 1 AND Table 2 HERE>

Univariable regression analyses

Results from the univariable linear regression analyses are presented in Table 1. Concerns about falling had the strongest effect (based on the standardized regression coefficients, β) on perceived walking difficulties at the 3-year follow-up ($\beta = 0.721$, $p < 0.001$), followed by perceived balance problems while dual tasking ($\beta = 0.582$, $p < 0.001$).

Multivariable regression analyses

Model 1 (controlled for age)

The multivariable linear regression analysis (controlled for age) identified four independent variables that predicted perceived walking difficulties three years later. The variable with the strongest effect was concerns about falling ($\beta = 0.467$), followed by perceived balance problems while dual tasking ($\beta = 0.265$), pain ($\beta = 0.137$) and postural instability ($\beta = 0.116$). All four variables were significant predictive factors. The model accounted for 61.7% of the variance (adjusted R^2) in Walk-12G scores at the 3-year follow-up. See Table 3 for further details.

Table 3

Multivariable linear regression analyses with Walk-12G at 3-year follow-up as the dependent variable:
Model I (controlled for age at baseline), $n = 147$

Independent variables (assessed at baseline) [†]	B (95% CI)	P-value	β
Concerns about falling (FES-I)	0.479 (0.348, 0.610)	< 0.001	0.467
Dual task: perceived balance problems (yes = 1)	6.50 (3.59, 9.41)	< 0.001	0.265
Bothered by pain (yes = 1)	3.43 (0.753, 6.01)	0.012	0.137
Postural instability (item 30, UPDRS III, scores ≥ 1 , yes = 1)	3.22 (0.292, 6.15)	0.031	0.116
<i>Age</i>	<i>0.222 (0.072, 0.373)</i>	0.004	<i>0.165</i>
R^2 63.0%; Adjusted R^2 61.7%			
Walk-12G = Generic Walk-12 (0–42, higher = worse); B = unstandardized regression coefficient; β = standardized regression coefficient; FES-I = Falls Efficacy Scale-International (16–64, higher = worse); UPDRS III = Unified Parkinson's Disease Rating Scale, motor examination (item scores 0–4, higher = worse; those who scored ≥ 1 on item 30 were classified as having postural instability).			
[†] The following 13 independent variables were included in the initial model: sex; concerns about falling; perceived balance problems while dual tasking; postural instability; bradykinesia; freezing of gait; lower extremity function; orthostatism; pain; cognitive functioning; fatigue; general self-efficacy; depressive symptoms.			
P-values below 0.05 are bolded.			
Controlling factors are written in italic.			

< PLEASE INSERT Table 3 HERE >

Model 2 (controlled for age and baseline Walk-12G scores)

The second model (controlled for age and baseline Walk-12G total scores) included six independent variables that predicted a change in perceived walking difficulties three years later, whereof two were statistically significant; the strongest predictor was perceived balance problems while dual tasking ($\beta = 0.180$), followed by postural instability ($\beta = 0.098$). The remaining four variables in the model did not reach statistical significance: global cognitive functioning ($p = 0.059$), fatigue ($p = 0.065$), pain ($p = 0.070$)

and lower extremity function ($p = 0.080$). The model accounted for 67.6% of the variance (adjusted R^2) in Walk-12G scores at the 3-year follow-up. See Table 4 for further details.

Table 4

Multivariable linear regression analyses with Walk-12G at 3-year follow-up as the dependent variable:
Model II (controlled for age and Walk-12G scores at baseline), $n = 147$

Independent variables (assessed at baseline) [†]	B (95% CI)	P-value	β
Dual task: perceived balance problems (yes = 1)	4.43 (1.56, 7.30)	0.003	0.180
Postural instability (item 30, UPDRS III, scores ≥ 1 , yes = 1)	2.75 (0.025, 5.48)	0.048	0.098
Global cognitive functioning (MoCA)	-0.375 (-0.764, 0.014)	0.059	-0.097
Fatigue (yes = 1)	2.53 (-0.156, 5.22)	0.065	0.104
Bothered by pain (yes = 1)	2.36 (-0.194, 4.93)	0.070	0.094
Worse lower extremity function (Five chair stands test ≥ 16.0 sec, yes = 1) [‡]	-2.25 (-4.76, 0.268)	0.080	-0.093
<i>Age</i>	<i>0.239 (0.098, 0.381)</i>	0.001	<i>0.177</i>
<i>Perceived walking difficulties (Walk-12G), baseline</i>	<i>0.604 (0.452, 0.757)</i>	<i>< 0.001</i>	<i>0.532</i>
R^2 69.4%; Adjusted R^2 67.6%			
Walk-12G = Generic Walk-12 (0–42, higher = worse); B = unstandardized regression coefficient; β = standardized regression coefficient; UPDRS III = Unified Parkinson's Disease Rating Scale, motor examination (item scores 0–4, higher = worse; those who scored ≥ 1 on item 30 were classified as having postural instability).			
[†] The following 13 independent variables were included in the initial model: sex; concerns about falling; perceived balance problems while dual tasking; postural instability; bradykinesia; freezing of gait; lower extremity function; orthostatism; pain; cognitive functioning; fatigue; general self-efficacy; depressive symptoms.			
[‡] 12 participants did not manage the test. These were categorized as having worse lower extremity function (i.e. ≥ 16 seconds)			
P-values below 0.05 are bolded.			
Controlling factors are written in italic.			

Both regression models fulfilled the assumptions for linear regression.

< PLEASE INSERT Table 4 HERE >

Discussion

This is the first study that investigates how perceived walking difficulties evolve over time in people with PD, including identifying predictive factors. Our results showed that perceived walking difficulties increased significantly over 3 years. The first regression model (controlled for age) showed that concerns about falling was the strongest predictive factor for perceived walking difficulties, followed by perceived balance problems while dual tasking, being bothered by pain and having postural instability. The second model (controlled for age and baseline Walk-12G scores) showed that perceived balance problems while dual tasking was the strongest predictive factor for a change in perceived walking difficulties, followed by postural instability.

The mean Walk-12G score increased by 3.9 points over a 3-year period, which exceeds the measurement error (SEM) presented in this study as well as in a previous PD study ²¹. The level of perceived walking difficulties in our sample at baseline seems to be in line with previous PD studies: the Walk-12G mean score was 14.7 in the present study as compared to 13-15.5 in previous studies ^{21,29,35}. However, one study reported a considerably lower Walk-12G score: median 8 (q1-q3 4.5–21). This might be explained by a shorter PD duration (mean 5 years vs. median 8 years in the present study) and less motor symptoms (UPDRS III median 13 vs. 28 in the present study; data not presented) ³⁶.

All dichotomous independent variables showed an effect on perceived walking difficulties that exceed the measurement error. For concerns about falling, participants need to change their FES-I score at least 5 points in order to achieve an effect that exceeds the measurement error of Walk-12G. It should be noted that the possible total score of FES-I ranges from 16–64. Thus, a changed score of 5 points corresponds to 10% change in relation to the scoring range.

That concerns about falling was the strongest predictive factor of perceived walking difficulties is in line with prior cross-sectional studies, which described that fear of falling relates to walking difficulties in people with PD ^{29,36}. In the current study, concerns about falling did not predict a change in perceived walking difficulties, i.e. when controlling for baseline Walk-12G scores. Controlling for a variable in a multivariable regression analysis means that the variable is included in all steps of the analysis, as well as in the final regression model. In the current study, FES-I scores were highly correlated with Walk-12G scores at baseline ($r_s = 0.870$), and this multicollinearity might explain why concerns about falling did not independently predict a change in perceived walking difficulties. Similarly, a previous study based on the same sample identified perceived walking difficulties as the strongest predictive factor of concerns about falling (FES-I), but it failed to predict a change in concerns about falling when controlling for baseline FES-I scores ¹⁹. Perceived walking difficulties and concerns about falling are interconnected and adjacent aspects, but they are not interchangeable constructs. Perceived walking difficulties focus on problems connected to walking ability, whereas FES-I targets concerns about falling while performing 16 different activities. In FES-I, five out of the 16 items explicitly mention walking and an additional item addresses stairclimbing. The remaining 10 items address concerns about falling while for example getting dressed

or undressed, preparing simple meals, reaching for something above your head or on the ground, visiting a friend or relative, and going out to a social event ²⁷.

Perceived balance problems while dual tasking was the second strongest predictor of perceived walking difficulties, and it was the strongest predictor for a change in perceived walking difficulties. Prior studies showed that dual tasking negatively affects objective gait measures (e.g. gait speed, gait variability, double support time and gait rhythmicity) in people with PD ^{37,38}. On the other hand, dual task training can be used to increase the level of difficulty when training gait and balance. Some studies suggest that dual task training has a positive effect on objective gait measures (e.g. dual task gait velocity, stride length and cadence) in people with PD ^{39,40}. Those who seems to benefit the most of dual task training are those with low initial gait speed when dual tasking and those with better cognitive functioning ³⁹. Interestingly, a study of highly challenging balance training, which included dual tasking, showed statistical significant improvements in balance performance and gait speed, but detected no improvements in any of the used patient reported outcomes, i.e. Walk-12G and rating scales targeting balance confidence and health-related quality of life ³⁵. Their findings might be due to that the intervention effect was considered clinically small, and the effect might therefore not transfer to perceived aspects such as Walk-12G scores. In other words, a potential explanation might be that objective changes in for example gait speed require large and/or long lasting changes in order to be reflected in patient-reported outcomes.

Pain and postural instability predicted perceived walking difficulties, and postural instability also predicted a change in perceived walking difficulties. Pain is a non-motor symptom that can affect up to 85% of people with PD, and it is most frequently located in the lower limbs ⁴¹. Pain in people with PD can result in activity limitations such as walking difficulties ⁴², and it has been shown to be negatively associated with quality of life ⁴³. In a prior cross-sectional study based on the same larger project as the present study (i.e. "Home and Health in People Ageing with Parkinson's disease"), both pain and perceived walking difficulties were shown to be associated with decreased life-space mobility ⁴⁴. All considered, pain deserves attention at clinical follow-ups. Management of pain in people with PD may for example include medication, cognitive strategies or exercise ^{42,45}.

In this study, postural instability was assessed by using item 30 of UPDRS part III; it is intended to assess the righting reflex and the reactive "response to a sudden posterior displacement produced by pull on shoulders" while standing erect with eyes open and feet slightly apart ²⁴. That both item 30 and perceived balance problems while dual tasking affect perceived walking difficulties highlight the importance of addressing balance problems in people with PD. Not the least since anti-PD medication insufficiently affects postural instability ⁴⁶. A meta-analysis found that physical exercise had a small positive effect on postural instability in people with PD, and "highly-challenging" balance training was advocated ⁴⁷.

It needs to be noted that global cognitive functioning was significantly associated with perceived walking difficulties in univariable regression analysis, and close to significantly associated in model 2 (i.e.

multivariable regression analysis). More studies are needed that address various cognitive domains in relation to perceived walking difficulties in order to further explore the potential impact of cognitive function on walking in people with PD.

Methodological considerations

At baseline, 243 participants completed the Walk-12G questionnaire and 61.3% of those completed the 3-year follow-up. There are dropouts in all longitudinal studies, which can affect the external validity of the findings. We have previously reported that those who completed the assessments at both time points were significantly younger and had shorter PD-duration than those who were lost for follow-up¹⁹.

Twelve participants that did not manage the Five chair stands test were included in the group of participants categorized as having worse lower extremity function. However, there might be other reasons than poor lower extremity function that made them unable to complete the test. The categorization was done since excluding them might have rendered a final sample that was skewed towards having a better lower extremity functioning.

The independent variables in the present study were selected based on theoretical reasoning as well as on the results from previous cross-sectional studies^{16,17}. The regression models in our study explained 61.7% and 67.6% of the variance in the Walk-12G scores, respectively. This means that there are additional factors than those studied that can predict perceived walking difficulties. Future studies are needed to explore the effect of e.g. visual impairments on perceived walking difficulties in people with PD.

Conclusions

This is the first follow-up study that investigates perceived walking difficulties in people with PD, including identifying predictive factors. Perceived walking difficulties increased over a 3-year period. All identified predictors are modifiable factors: concerns about falling, perceived problems maintaining balance while dual tasking, pain and postural instability. Future intervention studies that address these factors need to confirm their preventative effect on perceived walking difficulties, i.e. as the primary outcome.

Abbreviations

β
standardized regression coefficients; B:unstandardized regression coefficients; FES-I:Falls Efficacy Scale-International; FOG:Freezing of gait; FOGQsa:self-administered version of the Freezing of Gait Questionnaire; GDS-15:Geriatric Depression Scale; GSE:General Self-Efficacy Scale; MoCA:Montreal Cognitive Assessment; NMSQuest:Non-Motor Symptoms Questionnaire; NHP-EN:Nottingham Health Profile, energy subscale; PD:Parkinson's disease; SEM:standard error of measurement; UPDRS:Unified Parkinson's Disease Rating Scale; Walk-12G:Generic Walk12.

Declarations

Ethics approval and consent to participate

The participants initially received written information about the study, including a letter of invitation to participate. All potential participants thereafter received oral information (i.e. on phone by a health care professional), and were given the possibility to pose questions and time to consider whether they wanted to participate or not. Written informed consent was obtained from all participants and the project was conducted in accordance with the Helsinki Declaration. This study was approved by the regional ethical review board in Lund, Sweden (No. 2012/558; 2015/611).

Consent for publication

Not applicable.

Availability of data and materials

The data used in this study contains sensitive information about the participants and the study participants did not provide consent for public data sharing. The current approval by the Regional Ethical Review Board in Lund, Sweden (No. 2012/558) does not include data sharing. A minimal data set could be shared by request from a qualified academic investigator for the sole purpose of replicating the present study, provided the data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Swedish Ethical Review Authority.

Competing interests

The authors declare that they have no competing interests

Funding

The HHPD project was funded by the Strategic Research Area in neuroscience (MultiPark) at Lund University, the Swedish Research Council, the Ribbingska Foundation in Lund, the Greta and Johan Kock Foundation, the Swedish Association of Persons with Neurological Disabilities (NHR), the Swedish Parkinson Foundation, the Norrbacka-Eugenia Foundation, NEURO Sweden, and the Crafoord Foundation. This study was conducted within the context of the Centre for Ageing and Supportive Environments (CASE) at Lund University, funded by the Swedish Council for Working Life and Social Research (FORTE). SB Jonasson was funded by the Academy of Caring Sciences at Skåne University Hospital and Translational Clinical Research at Skåne County Council 2019–2022. None of the funding bodies were involved in designing the study, collection, analysis or interpretation of data, or writing of the manuscript.

Authors' Contributions

MLR, SBJ and NMC were involved in designing the study, which is a part of the larger project “Home and Health in People Ageing with Parkinson’s Disease” (MHN is principal investigator). MLR conducted the initial analyses of data; the analyses were scrutinized by MHN, SBJ and SU. All co-authors assisted in data interpretation. MLR conducted the initial draft of the manuscript. All authors were involved in preparing the paper and approved the final manuscript.

Acknowledgements

The authors wish to thank the participants for their cooperation, and the data collectors for their contribution.

References

1. Mirelman A, Bonato P, Camicioli R, et al. Gait impairments in Parkinson's disease. *The Lancet Neurology*. 2019;18(7):697–708.
2. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. *Movement Disorders*. 2008;23(6):790–6.
3. Tan DM, McGinley JL, Danoudis ME, Iansek R, Morris ME. Freezing of Gait and Activity Limitations in People With Parkinson's Disease. *Archives of Physical Medicine Rehabilitation*. 2011;92(7):1159–65.
4. Tan D, Danoudis M, McGinley J, Morris ME. Relationships between motor aspects of gait impairments and activity limitations in people with Parkinson's disease: a systematic review. *Parkinsonism related disorders*. 2012;18(2):117–24.
5. Creaby MW, Cole MH. Gait characteristics and falls in Parkinson's disease: A systematic review and meta-analysis. *Parkinsonism related disorders*. 2018;57:1–8.
6. Hammarlund CS, Andersson K, Andersson M, Nilsson MH, Hagell P. The significance of walking from the perspective of people with Parkinson's disease. *Journal of Parkinson's disease*. 2014;4(4):657–63.
7. Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. *JAMA neurology*. 2014;71(7):884–90.
8. Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype. *Movement Disorders*. 2015;30(3):359–67.
9. Baron EI, Miller Koop M, Streicher MC, Rosenfeldt AB, Alberts JL. Altered kinematics of arm swing in Parkinson's disease patients indicates declines in gait under dual-task conditions. *Parkinsonism related disorders*. 2018;48:61–7.
10. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. *Journal of neurology neurosurgery psychiatry*. 2002;72(6):721–5.

11. Nemanich ST, Duncan RP, Dibble LE, et al. Predictors of gait speeds and the relationship of gait speeds to falls in men and women with Parkinson disease. *Parkinson's disease*. 2013;2013:141720–0.
12. O'Dowd S, Galna B, Morris R, et al. Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson's Disease Cohort. *Journal of Parkinson's disease*. 2017;7(3):465–70.
13. Pretzer-Aboff I, Galik E, Resnick B. Parkinson's disease: barriers and facilitators to optimizing function. *Rehabil Nurs*. 2009;34(2):55–63, 83.
14. Lamont RM, Morris ME, Woollacott MH, Brauer SG. Community walking in people with Parkinson's disease. *Parkinson's disease*. 2012;2012:856237.
15. Parry R, Buttelli O, Riff J, et al. "The whole perimeter is difficult": Parkinson's disease and the conscious experience of walking in everyday environments. *Disability rehabilitation*. 2019;41(23):2784–91.
16. Leavy B, Löfgren N, Nilsson M, Franzén E. Patient-reported and performance-based measures of walking in mild–moderate Parkinson's disease. *Brain and behavior*. 2018;8(9).
17. Kader M, Ullen S, Iwarsson S, Odin P, Nilsson MH. Factors Contributing to Perceived Walking Difficulties in People with Parkinson's Disease. *Journal of Parkinson's disease*. 2017;7(2):397–407.
18. Nilsson MH, Iwarsson S. Home and health in people ageing with parkinson's disease: Study protocol for a prospective longitudinal cohort survey study. *BMC neurology*. 2013;13.
19. Lindh-Rengifo M, Jonasson SB, Mattsson N, Ullén S, Nilsson MH. Predictive Factors of Concerns about Falling in People with Parkinson's Disease: A 3-Year Longitudinal Study. *Parkinson's disease*. 2019;2019:9.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology*. 1967;17(5):427–42.
21. Bladh S, Nilsson MH, Hariz GM, Westergren A, Hobart J, Hagell P. Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease. *Journal of neurology*. 2012;259(4):729–38.
22. Suteerawattananon M, Protas EJ. Reliability of outcome measures in individuals with Parkinson's Disease. *Physiotherapy theory practice*. 2000;16(4):211–8.
23. Duncan RP, Leddy AL, Earhart GM. Five times sit-to-stand test performance in Parkinson's disease. *Archives of physical medicine rehabilitation*. 2011;92(9):1431–6.
24. Members of the UPDRS Development Committee Unified Parkinson's Disease Rating Scale Fahn S, Elton RL. Members of the UPDRS Development Committee Unified Parkinson's Disease Rating Scale, in *Recent Developments in Parkinson's Disease*. Volume 2. Fahn S, et al., Editors. MacMillan Healthcare Information. Florham Park, NJ. 1987. pp. 153–163, 293–304. 1987.
25. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. *Journal of the American Geriatrics Society*. 2005;53(4):695–9.

26. Schwarzer RJM. Generalized Self-Efficacy scale. In Measures in health psychology: A user's portfolio. Causal and control beliefs. J. Weinman, S. Wright, & M. Johnston, eds. *Windsor K: NFER-NELSON*, 1995:35–37.
27. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). *Age ageing*. 2005;34(6):614–9.
28. Nilsson MH, Hariz GM, Wictorin K, Miller M, Forsgren L, Hagell P. Development and testing of a self administered version of the Freezing of Gait Questionnaire. *BMC neurology*. 2010;10:85.
29. Nilsson MH, Hariz GM, Iwarsson S, Hagell P. Walking ability is a major contributor to fear of falling in people with Parkinson's disease: implications for rehabilitation. *Parkinson's disease*. 2012:Article ID 713236..
30. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived health status: a validation study. *Journal of epidemiology community health*. 1980;34(4):281–6.
31. Hagell P, Hoglund A, Reimer J, et al. Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires. *Journal of pain symptom management*. 2006;32(5):420–32.
32. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Movement disorders: official journal of the Movement Disorder Society*. 2006;21(7):916–23.
33. Sheikh JIY. J.A.. Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. In *Clinical Gerontology: A Guide to Assessment and Intervention*. 1986.;5 (1–2):165–173.
34. Paker N, Bugdayci D, Goksenoglu G, Demircioglu DT, Kesiktas N, Ince N. Gait speed and related factors in Parkinson's disease. *J Phys Ther Sci*. 2015;27(12):3675–9.
35. Leavy B, Joseph C, Lofgren N, Johansson H, Hagstromer M, Franzen E. Outcome Evaluation of Highly Challenging Balance Training for People With Parkinson Disease: A Multicenter Effectiveness-Implementation Study. *Journal of neurologic physical therapy: JNPT*. 2020;44(1):15–22.
36. Lindholm B, Hagell P, Hansson O, Nilsson MH. Factors associated with fear of falling in people with Parkinson's disease. *BMC neurology*. 2014;14:19.
37. O'Shea S, Morris ME, Iansek R. Dual task interference during gait in people with Parkinson disease: effects of motor versus cognitive secondary tasks. *Physical therapy*. 2002;82(9):888–97.
38. Yogev G, Giladi N, Peretz C, Springer S, Simon ES, Hausdorff JM. Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects of gait are attention demanding? *European Journal of Neuroscience*. 2005;22(5):1248–56.
39. Strouwen C, Molenaar E, Munks L, et al. Determinants of Dual-Task Training Effect Size in Parkinson Disease: Who Will Benefit Most? *Journal of neurologic physical therapy: JNPT*. 2019;43(1):3–11.
40. De Freitas TB, Leite PHW, Doná F, Pompeu JE, Swarowsky A, Torriani-Pasin C. The effects of dual task gait and balance training in Parkinson's disease: a systematic review. *Physiotherapy theory and*

practice. 2018;1–9.

41. Broen MPG, Braaksma MM, Patijn J, Weber WEJ. Prevalence of pain in Parkinson's disease: A systematic review using the modified QUADAS tool. *Movement Disorders*. 2012;27(4):480–4.
42. Keus SHJMM, Graziano M. European Physiotherapy Guideline for Parkinson's disease. *KNGF/ParkinsonNet, the Netherlands*. 2014.
43. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: The relative importance of the symptoms. *Movement Disorders*. 2008;23(10):1428–34.
44. Rantakokko M, Iwarsson S, Slaug B, Nilsson MH. Life-Space Mobility in Parkinson's Disease: Associations with Motor and Non-Motor Symptoms. *The journals of gerontology Series A Biological sciences medical sciences*. 2019;74(4):507–12.
45. Allen NE, Moloney N, van Vliet V, Canning CG. The Rationale for Exercise in the Management of Pain in Parkinson's Disease. *Journal of Parkinson's disease*. 2015;5(2):229–39.
46. Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in Parkinson's disease: Effects on gait. *Parkinsonism related disorders*. 2016;31:3–13.
47. Klamroth S, Steib S, Devan S, Pfeifer K. Effects of Exercise Therapy on Postural Instability in Parkinson Disease: A Meta-analysis. *Journal of Neurologic Physical Therapy*. 2016;40(1):3–14.